Danaher Co. (NYSE:DHR) Shares Sold by Amarillo National Bank

Amarillo National Bank lessened its stake in shares of Danaher Co. (NYSE:DHR) by 5.1% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,675 shares of the conglomerate’s stock after selling 90 shares during the period. Amarillo National Bank’s holdings in Danaher were worth $418,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Cape Investment Advisory Inc. acquired a new stake in Danaher in the fourth quarter valued at approximately $25,000. Tsfg LLC lifted its position in shares of Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after acquiring an additional 88 shares during the period. BKM Wealth Management LLC bought a new position in shares of Danaher during the 4th quarter worth approximately $27,000. Wetzel Investment Advisors Inc. acquired a new position in Danaher in the fourth quarter valued at about $29,000. Finally, Redmont Wealth Advisors LLC bought a new stake in Danaher during the 1st quarter worth approximately $30,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on DHR shares. Barclays raised their price target on Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a report on Wednesday, April 24th. HSBC upgraded Danaher from a “hold” rating to a “buy” rating and upped their target price for the stock from $250.00 to $280.00 in a report on Wednesday, April 17th. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Citigroup lifted their price objective on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Finally, Robert W. Baird raised their target price on shares of Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 24th. Six investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat, Danaher has an average rating of “Moderate Buy” and an average target price of $268.67.

Danaher Trading Down 0.2 %

Shares of Danaher stock traded down $0.41 on Thursday, hitting $240.00. 1,935,837 shares of the company’s stock traded hands, compared to its average volume of 3,506,555. Danaher Co. has a one year low of $182.09 and a one year high of $269.11. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.85 and a quick ratio of 1.51. The company has a fifty day moving average of $255.67 and a two-hundred day moving average of $246.91. The company has a market capitalization of $177.77 billion, a price-to-earnings ratio of 40.68, a price-to-earnings-growth ratio of 3.68 and a beta of 0.83.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, beating the consensus estimate of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The company had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.62 billion. During the same quarter in the prior year, the company earned $2.36 EPS. The firm’s revenue for the quarter was down 2.6% compared to the same quarter last year. As a group, sell-side analysts expect that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be given a dividend of $0.27 per share. The ex-dividend date is Friday, June 28th. This represents a $1.08 annualized dividend and a dividend yield of 0.45%. Danaher’s payout ratio is 18.31%.

Insider Activity at Danaher

In other Danaher news, SVP Brian W. Ellis sold 4,000 shares of the stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $250.01, for a total value of $1,000,040.00. Following the transaction, the senior vice president now owns 29,830 shares in the company, valued at $7,457,798.30. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, CEO Rainer Blair sold 47,175 shares of the firm’s stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total value of $11,756,953.50. Following the transaction, the chief executive officer now owns 115,995 shares of the company’s stock, valued at approximately $28,908,273.90. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Brian W. Ellis sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $250.01, for a total value of $1,000,040.00. Following the sale, the senior vice president now directly owns 29,830 shares of the company’s stock, valued at $7,457,798.30. The disclosure for this sale can be found here. Insiders have sold a total of 148,783 shares of company stock worth $37,536,717 in the last 90 days. Corporate insiders own 10.90% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.